Aug 10, 2025, 19:39

CPRIT Recruitment of Established Investigators

CPRIT will fund Texas institutions to recruit world-class senior cancer researchers (typically full professor or equivalent) whose work has made outstanding, sustained contributions. The mechanism strengthens Texas’s research capacity with strong institutional commitment and a focus on CPRIT priority areas.

Eligibility Criteria:

Applicant must be a Texas-based not-for-profit research institution; public or private companies are not eligible.
PI must be nominated by institutional leadership (president/provost/VP for research/dean) and may be nominated by only one institution.
PI must hold a doctoral degree, be at the rank of professor (or equivalent), not reside in Texas at submission, and devote at least 70% effort to research; co-investigators are not allowed.
Collaborating organizations may be inside or outside Texas, but non-Texas entities cannot receive CPRIT funds.
Institutional commitment must equal or exceed 50% of the proposed CPRIT award for the full duration; matching funds equal to one-half of CPRIT funding must be demonstrated at contract execution and annually.

Funding Details:

Up to USD 6,000,000 total costs over up to 5 years; non-renewable. Indirect costs capped at 5% of the total award (≈ 5.263% of direct costs). FY26 individual salary cap: USD 225,000.
Funds may support PI salary and extraordinary first-year equipment (with justification); construction/renovation is not allowed. Travel for up to 2 project staff to CPRIT’s conference is permitted.

Deadline:

Application receipt window: June 23, 2025 – June 22, 2026 (continuous cycles).

Where to Go for Further Information:

Apply via CPRIT’s CARS portal.
Scientific/programmatic questions: [email protected].

academic research cancer cancer research funding CPRIT faculty recruitment indirect cost cap institutional commitment matching funds OncoDaily Oncology Recruitment of Established Investigators REI senior investigators Texas

IMvigor011 Trial Reports ctDNA as Predictor of Response to Adjuvant Atezolizumab in Bladder Cancer

Ruben Mesa is Starting a New Position as President of Cancer National Service Line at Advocate Health

Patrick Soon-Shiong: 30 Years and $3B Toward a Universal Cancer Fighter

Dana Dornsife: After 19 Years, Lazarex Cancer Foundation Is Shuttering Because of Lack of Funding

Matt Sherer: ASCO Supports Permanent Medicare Telehealth